Change of Board Structure

30 June 2011

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

                           Change of Board Structure                           

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer
vaccines, announces that Dr Richard Goodfellow has been appointed Joint Chief
Executive Officer as the Company enters the next phase of its development.

The Board recognises that Dr Goodfellow's position has evolved into a separate
leadership role from that held by Professor Lindy Durrant, including the
management of Scancell's commercial activities, investor and City liaison and
management of the Company's exit strategy.

David Evans, Chairman, commented:

"The Board recognises Richard's skills and endeavours as being distinct and
separate from Lindy's. He continues to show exceptional leadership built on
hard work and a passion to drive shareholder value."

For further information contact:

Scancell Holdings Plc                          + 44 (0)207 245 1100
                                                                   
Professor Lindy Durrant                                            
                                                                   
Hansard Communications                         + 44 (0)207 245 1100
                                                                   
Adam Reynolds/Guy McDougall                                        
                                                                   
Zeus Capital - Nominated Adviser               + 44 (0)161 831 1512
                                                                   
Ross Andrews/Tom Rowley                                            
                                                                   
XCAP Securities Plc - Broker                    [phone]
                                                                   
John Belliss/Parimal Kumar                                         

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1, which entered clinical trials
in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.